ArticlePharmaceuticals (Basel, Switzerland)2019
Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models.
Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Ginsenosides fromJournal of ginseng research · 2026Review
- Natural Products as Novel Therapeutic Agents for Triple-Negative Breast Cancer: Current Evidence, Mechanisms, Challenges, and Opportunities.Molecules (Basel, Switzerland) · 2025Review
- Aquaporins in colorectal cancer: exploring their role in tumorigenesis, metastasis, and drug response.Human cell · 2024Review
- Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3.Journal of ginseng research · 2024Article
- Ginsenoside Rg3: A Review of its Anticancer Mechanisms and Potential Therapeutic Applications.Current topics in medicinal chemistry · 2024Review
- A deep learning-based pipeline for analyzing the influences of interfacial mechanochemical microenvironments on spheroid invasion using differential interference contrast microscopic images.Materials today. Bio · 2023Article
- Article
- Immunomodulatory, Anti-Inflammatory, and Anti-Cancer Properties of Ginseng: A Pharmacological Update.Molecules (Basel, Switzerland) · 2023Review
- Production of a Novel Protopanaxatriol-Type Ginsenoside by Yeast Cell Factories.Bioengineering (Basel, Switzerland) · 2023Article
- Anti-cancer effect and potential microRNAs targets of ginsenosides against breast cancer.Frontiers in pharmacology · 2022Review
- Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses.Frontiers in oncology · 2022Article
- Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments.Cancers · 2021Article
- Network Pharmacology-Based Approach to Investigate the Molecular Targets of Sinomenine for Treating Breast Cancer.Cancer management and research · 2021Article
- Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Natural Health Products (NHP's) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends.International journal of molecular sciences · 2020Review
- Anti-Angiogenic Properties of Ginsenoside Rg3.Molecules (Basel, Switzerland) · 2020Review
- Bactericidal and In Vitro Cytotoxicity ofPharmaceuticals (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Ginsenoside Rg3 (Rg3) has two epimers, 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3), and while Rg3 itself has been reported to have anti-cancer properties, few studies have been reported on the anti-cancer effects of the different epimers. The aim was to investigate the stereoselective effects of the Rg3 epimers on triple negative breast cancer (TNBC) cell lines, tested using cell-based assays for proliferation, apoptosis, cell cycle arrest, migration and invasion. Molecular docking showed that Rg3 interacted with the aquaporin 1 (AQP1) water channel (binding score -9.4 kJ mol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.